Wireless IoT leader delivers $251 million in revenue and strong earnings growth AUSTIN, Texas – November 10, 2026 – Silicon Labs (NASDAQ: SLAB), the leading innovator in low-power wireless, reported financial results for the third quarter, which ended October 3, 2026.
“We delivered strong third-quarter results, with revenue up 10% sequentially, underpinned by broad-based growth across many end applications and another record quarter for medical revenue as known customer ramps continued,” said Matt Johnson, President and Chief Executive Officer. “Earnings significantly outpaced revenue growth, a result of strong operational execution by the team. Looking ahead, our current backlog and design-win ramps position us for continued revenue growth and meaningful earnings expansion.”
Third Quarter Financial Highlights
•Revenue was $251 million, up 22% year-over-year
•Industrial & Commercial revenue was $141 million, up 20% year-over-year •Home & Life revenue was $110 million, up 24% year-over-year •Bookings imply a healthy demand environment, while distributor inventory declined further to a multi-year low and end customer inventory was near record lows during the quarter •Medical revenue reached a new quarterly record, increasing 48% sequentially and more than 300% year-over-year •GAAP diluted earnings per share was $0.26, compared with a loss of $0.30 in the year-ago quarter •Non-GAAP diluted earnings per share was $1.05, up 228% over the comparable period last year Results on a GAAP basis:
•GAAP gross margin was 60.8%
•GAAP operating expenses were $145 million
•GAAP operating income was $8 million
•GAAP diluted earnings per share was $0.26
Results on a non-GAAP basis, excluding the impact of stock compensation, amortization of acquired intangible assets, merger-related costs, and certain other items as set forth in the below GAAP to Non-GAAP reconciliation tables were as follows:
•Non-GAAP gross margin was 61.0%
•Non-GAAP operating expenses were $113 million
•Non-GAAP operating income was $40 million
•Non-GAAP diluted earnings per share was $1.05
Due to the announced pending acquisition of Silicon Labs by Texas Instruments, Silicon Labs has suspended providing forward-looking guidance.
About Silicon Labs
Silicon Labs (NASDAQ: SLAB) is the leading innovator in low-power wireless connectivity, building embedded technology that connects devices and improves lives. Merging cutting-edge technology into the world's most highly integrated SoCs, Silicon Labs provides device makers the solutions, support, and ecosystems needed to create advanced edge connectivity applications. Headquartered in Austin, Texas, Silicon Labs has operations in over 16 countries and is the trusted partner for innovative solutions in the smart home, industrial IoT, and smart cities markets. Learn more at silabs.com.
Forward-Looking Statements
This press release contains forward-looking statements regarding Silicon Labs’ current expectations, which are based on its current views and assumptions. The words “believe”, “estimate”, “expect”, “intend”, “anticipate”, “plan”, “project”, “will”, and similar phrases as they relate to Silicon Labs are intended to identify such forward-looking statements, although the absence of such words does not necessarily mean a statement is not forward looking. These forward-looking statements include, but are not necessarily limited to, Silicon Labs’ expectations regarding its near- and long-term strength and continued revenue growth and earnings expansion and are subject to various risks and uncertainties that could cause actual results to differ materially from expectations that are expressed or implied herein. Among the factors that could cause actual results to differ materially from those in the forward-looking statements are the following: our ability to complete the merger with Texas Instruments within the time frame expected, or at all, as well as potential disruptions in our business and restrictions on our activities during the pendency of the merger; fluctuating changes in global trade policies, including the imposition of tariffs, duties, trade sanctions, or other barriers to international commerce; the impact of the current global memory chip shortage; the competitive and cyclical nature of the semiconductor industry; the challenging macroeconomic environment, including disruptions in the financial services industry; geographic concentration of manufacturers, assemblers, test service providers and customers in Asia that subjects Silicon Labs’ business and results of operations to risks of natural disasters, epidemics or pandemics, war and political unrest; risks that demand and the supply chain may be adversely affected by military conflict (including in the Middle East, and between Russia and Ukraine), terrorism, sanctions or other geopolitical events globally (including in the Middle East, and conflict between Taiwan and China); risks that Silicon Labs may not be able to maintain its historical growth; quarterly fluctuations in revenues and operating results; difficulties developing new products that achieve market acceptance; risks associated with international activities (including trade barriers, particularly with respect to China); intellectual property litigation risks; risks associated with acquisitions and divestitures; product liability risks; difficulties managing and/or obtaining sufficient supply from Silicon Labs’ distributors, manufacturers and subcontractors; dependence on a limited number of products; absence of long-term commitments from customers; inventory-related risks; difficulties managing international activities; risks that Silicon Labs may not be able to manage strains associated with its growth; credit risks associated with its accounts receivable; dependence on key personnel; stock price volatility; the impact of public health crises on the U.S. and global economy; debt-related risks; capital-raising risks; the timing and scope of share repurchases and/or dividends; average selling prices of products may decrease significantly and rapidly; information technology risks; cyber-attacks against Silicon Labs’ products and its networks; risks associated with any material weakness in our internal controls over financial reporting; risks relating to compliance with laws and regulations; and other factors that are detailed in the SEC filings of Silicon Laboratories Inc. Silicon Labs disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. References in this press release to Silicon Labs shall mean Silicon Laboratories Inc.
Note to editors: Silicon Laboratories, Silicon Labs, the “S” symbol, and the Silicon Labs logo are trademarks of Silicon Laboratories Inc. All other product names noted herein may be trademarks of their respective holders.
For more information: Silicon Labs Investor Relations, investor.relations@silabs.com Silicon Laboratories Inc.
Condensed Consolidated Statements of Operations
(In thousands, except per share data)
(Unaudited)
| Three Months Ended | Nine Months Ended | ||||||||||||||||||||||
| October 3, 2026 | October 4, 2025 | October 3, 2026 | October 4, 2025 | ||||||||||||||||||||
| Revenues | $ | 250,892 | $ | 205,999 | $ | 692,581 | $ | 576,558 | |||||||||||||||
| Cost of revenues | 98,314 | 86,980 | 272,331 | 251,653 | |||||||||||||||||||
| Gross profit | 152,578 | 119,019 | 420,250 | 324,905 | |||||||||||||||||||
| Operating expenses: | |||||||||||||||||||||||
| Research and development | 93,174 | 87,685 | 276,784 | 263,725 | |||||||||||||||||||
| Selling, general and administrative | 51,453 | 43,676 | 163,263 | 128,469 | |||||||||||||||||||
| Operating expenses | 144,627 | 131,361 | 440,047 | 392,194 | |||||||||||||||||||
| Operating income (loss) | 7,951 | (12,342) | (19,797) | (67,289) | |||||||||||||||||||
| Other income (expense): | |||||||||||||||||||||||
| Interest income and other, net | 3,185 | 3,046 | 9,300 | 10,672 | |||||||||||||||||||
| Interest expense | (226) | (226) | (709) | (761) | |||||||||||||||||||
| Income (loss) before income taxes | 10,910 | (9,522) | (11,206) | (57,378) | |||||||||||||||||||
| Provision for income taxes | 2,059 | 414 | 6,432 | 4,845 | |||||||||||||||||||
| Net income (loss) | $ | 8,851 | $ | (9,936) | $ | (17,638) | $ | (62,223) | |||||||||||||||
| Earnings (loss) per share: | |||||||||||||||||||||||
| Basic | $ | 0.27 | $ | (0.30) | $ | (0.53) | $ | (1.91) | |||||||||||||||
| Diluted | $ | 0.26 | $ | (0.30) | $ | (0.53) | $ | (1.91) | |||||||||||||||
| Weighted-average common shares outstanding: | |||||||||||||||||||||||
| Basic | 33,376 | 32,835 | 33,182 | 32,656 | |||||||||||||||||||
| Diluted | 33,752 | 32,835 | 33,182 | 32,656 | |||||||||||||||||||
Non-GAAP Financial Measurements
In addition to the GAAP results provided throughout this document, Silicon Labs has provided non-GAAP financial measurements on a basis excluding non-cash and other charges and benefits. Details of these excluded items are presented in the tables below, which reconcile the GAAP results to non-GAAP financial measurements.
The non-GAAP financial measurements do not replace the presentation of Silicon Labs’ GAAP financial results. These measurements provide supplemental information to assist management and investors in analyzing Silicon Labs’ financial position and results of operations. Silicon Labs has chosen to provide this information to investors to enable them to perform meaningful comparisons of past, present and future operating results and as a means to emphasize the results of core on-going operations.
Unaudited Reconciliation of GAAP to Non-GAAP Financial Measures (In thousands, except per share data) *Represents pre-tax amounts ** Represents the application of an 18% non-GAAP tax rate Silicon Laboratories Inc.
| Three Months Ended October 3, 2026 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Non-GAAP Income Statement Items | GAAP Measure | GAAP Percent of Revenue | Stock Compensation Expense | Intangible Asset Amortization | Merger-Related Costs | Non-GAAP Measure | Non-GAAP Percent of Revenue | |||||||||||||||||||||||||||||||||||||||||||
| Revenues | $ | 250,892 | ||||||||||||||||||||||||||||||||||||||||||||||||
| Gross profit | 152,578 | 60.8 | % | $ | 459 | $ | — | $ | — | $ | 153,037 | 61.0 | % | |||||||||||||||||||||||||||||||||||||
| Research and development | 93,174 | 37.1 | % | 11,996 | 2,295 | 3,623 | 75,260 | 30.0 | % | |||||||||||||||||||||||||||||||||||||||||
| Selling, general and administrative | 51,453 | 20.5 | % | 10,594 | — | 3,281 | 37,578 | 15.0 | % | |||||||||||||||||||||||||||||||||||||||||
| Operating expenses | 144,627 | 57.6 | % | 22,590 | 2,295 | 6,904 | 112,838 | 45.0 | % | |||||||||||||||||||||||||||||||||||||||||
| Operating income | 7,951 | 3.2 | % | 23,049 | 2,295 | 6,904 | 40,199 | 16.0 | % | |||||||||||||||||||||||||||||||||||||||||
| Three Months Ended October 3, 2026 | ||||||||||||||||||||||||||||||||||||||||||||
| Non-GAAP Earnings Per Share | GAAP Measure | Stock Compensation Expense* | Intangible Asset Amortization* | Merger-Related Costs* | Income Tax Adjustments** | Non- GAAP Measure | ||||||||||||||||||||||||||||||||||||||
| Net income (loss) | $ | 8,851 | $ | 23,049 | $ | 2,295 | $ | 6,904 | $ | (5,710) | $ | 35,389 | ||||||||||||||||||||||||||||||||
| Diluted shares outstanding | 33,752 | 33,752 | ||||||||||||||||||||||||||||||||||||||||||
| Diluted earnings per share | $ | 0.26 | $ | 1.05 | ||||||||||||||||||||||||||||||||||||||||
Condensed Consolidated Balance Sheets
(In thousands, except per share data)
(Unaudited)
| October 3, 2026 | January 3, 2026 | ||||||||||
| Assets | |||||||||||
| Current assets: | |||||||||||
| Cash and cash equivalents | $ | 423,013 | $ | 364,222 | |||||||
| Short-term investments | 16,828 | 79,400 | |||||||||
| Accounts receivable, net | 79,966 | 64,513 | |||||||||
| Inventories | 133,391 | 95,566 | |||||||||
| Prepaid expenses and other current assets | 71,421 | 70,316 | |||||||||
| Total current assets | 724,619 | 674,017 | |||||||||
| Property and equipment, net | 131,687 | 128,643 | |||||||||
| Goodwill | 376,389 | 376,389 | |||||||||
| Other intangible assets, net | 16,246 | 23,130 | |||||||||
| Other assets, net | 87,213 | 67,138 | |||||||||
| Total assets | $ | 1,336,154 | $ | 1,269,317 | |||||||
| Liabilities and Stockholders’ Equity | |||||||||||
| Current liabilities: | |||||||||||
| Accounts payable | $ | 68,860 | $ | 50,717 | |||||||
| Deferred revenue and returns liability | 9,804 | 5,359 | |||||||||
| Other current liabilities | 78,841 | 87,711 | |||||||||
| Total current liabilities | 157,505 | 143,787 | |||||||||
| Other non-current liabilities | 53,267 | 31,112 | |||||||||
| Total liabilities | 210,772 | 174,899 | |||||||||
| Commitments and contingencies | |||||||||||
| Stockholders’ equity: | |||||||||||
| Preferred stock – $0.0001 par value; 10,000 shares authorized; no shares issued | — | — | |||||||||
| Common stock – $0.0001 par value; 250,000 shares authorized; 33,384 and 32,955 shares issued and outstanding at October 3, 2026 and January 3, 2026, respectively | 3 | 3 | |||||||||
| Additional paid-in capital | 206,203 | 157,402 | |||||||||
| Retained earnings | 919,176 | 936,814 | |||||||||
| Accumulated other comprehensive income | — | 199 | |||||||||
| Total stockholders’ equity | 1,125,382 | 1,094,418 | |||||||||
| Total liabilities and stockholders’ equity | $ | 1,336,154 | $ | 1,269,317 | |||||||
Silicon Laboratories Inc.
Condensed Consolidated Statements of Cash Flows
(In thousands)
(Unaudited)
| Nine Months Ended | |||||||||||
| October 3, 2026 | October 4, 2025 | ||||||||||
| Operating Activities | |||||||||||
| Net loss | $ | (17,638) | $ | (62,223) | |||||||
| Adjustments to reconcile net loss to net cash provided by operating activities: | |||||||||||
| Depreciation of property and equipment | 18,154 | 18,769 | |||||||||
| Amortization of other intangible assets | 6,884 | 11,074 | |||||||||
| Stock-based compensation expense | 69,754 | 59,645 | |||||||||
| Deferred income taxes | 2,164 | 2,026 | |||||||||
| Changes in operating assets and liabilities: | |||||||||||
| Accounts receivable | (15,453) | (12,829) | |||||||||
| Inventories | (37,828) | 23,316 | |||||||||
| Prepaid expenses and other assets | (35,213) | 9,080 | |||||||||
| Accounts payable | 18,373 | 11,141 | |||||||||
| Other current liabilities and income taxes | 3,271 | 29,901 | |||||||||
| Deferred revenue and returns liability | 4,445 | 5,374 | |||||||||
| Other non-current liabilities | 20,285 | (7,916) | |||||||||
| Net cash provided by operating activities | 37,198 | 87,358 | |||||||||
| Investing Activities | |||||||||||
| Purchases of marketable securities | — | (34,790) | |||||||||
| Sales of marketable securities | — | 15,332 | |||||||||
| Maturities of marketable securities | 62,309 | 22,598 | |||||||||
| Purchases of property and equipment | (28,472) | (19,942) | |||||||||
| Proceeds from capital-related government incentives | 8,705 | — | |||||||||
| Purchase of other investment | — | (4,000) | |||||||||
| Net cash provided by (used in) investing activities | 42,542 | (20,802) | |||||||||
| Financing Activities | |||||||||||
| Payment of taxes withheld for vested stock awards | (28,710) | (14,907) | |||||||||
| Proceeds from the issuance of common stock | 7,761 | 8,147 | |||||||||
| Net cash used in financing activities | (20,949) | (6,760) | |||||||||
| Increase in cash and cash equivalents | 58,791 | 59,796 | |||||||||
| Cash and cash equivalents at beginning of period | 364,222 | 281,607 | |||||||||
| Cash and cash equivalents at end of period | $ | 423,013 | $ | 341,403 | |||||||